| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 12 Nov 2026 |
Form 4: Caveney Brian J, EVP, Pres of BLS, CMO & CSO
Sold 2,000 shares ($744K) |
| 10 Nov 2026 | 144 |
| 05 Nov 2026 |
Form 4: Vaughn Bryan T, EVP and President, Diagnostics
Sold 306 shares ($108K) |
| 04 Nov 2026 | 144 |
| 04 Nov 2026 |
8-K: Regulation FD Disclosure
BURLINGTON, N.C., (Nov. 4, 2026) — Labcorp Holdings, Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Co... |
| 03 Nov 2026 | 144 |
| 03 Nov 2026 |
Form 4: Parham Richelle P, Director
Sold 1,078 shares ($389K) |
| 03 Nov 2026 |
Form 4: Oyegunwa Akinbolade, EVP, CIO & CTO
Received 370 shares by exercise or conversion · Gave up 118 shares to cover exercise price or tax ($42K) |
| 03 Nov 2026 |
Form 4: Vaughn Bryan T, EVP and President, Diagnostics
Received 500 shares by exercise or conversion · Gave up 194 shares to cover exercise price or tax ($69K) |
| 30 Oct 2026 | 10-Q |
| 30 Oct 2026 | 144 |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
BURLINGTON, N.C., October 28, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2026 and updated its full-year ... |
| 21 Oct 2026 |
8-K: Regulation FD Disclosure
BURLINGTON, N.C., October 21, 2026 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of co... |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure
BURLINGTON, N.C., (Sept. 30, 2026) – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wedne... |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure
On September 21, 2026, the Centers for Medicare & Medicaid Services (“CMS”) released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting Access to Medicare Act (“PAMA”).... |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure
2©2026 Labcorp. All rights reserved. Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidan... |
| 03 Sep 2026 |
Form 4: Oyegunwa Akinbolade, EVP, CIO & CTO
Granted 750 Restricted Stock Unit |
| 03 Sep 2026 |
Form 4: Meltzer Jonathan C, EVP, COO
Granted 900 Restricted Stock Unit |
| 03 Sep 2026 |
Form 4: Vaughn Bryan T, EVP and President, Diagnostics
Granted 1,500 Restricted Stock Unit |
Loading...